Investor Presentaiton
Product
Superior Treatment to Blockbusters
FB825
ONENESS
Atopic dermatitis, Asthma
Dupixent
DUPIXENT
(dupilumab)
300-2-
DUPIXENT
(dupilumab)
Atopic dermatitis, Asthma
RINVOQ
RINVOG
ONENESS
Indication
Administration
SC
Dose
13 doses/ year (every 4
weeks)
Side effect
No major side effects
N/A
Cost
Target
Cεmx
N/A
2020 Global
sales
SC
Rheumatoid arthritis, Atopic dermatitis
Oral
26 doses/year (every 2 weeks) 365 tablets / year (daily dose)
Allergic reactions/ eye
problems
Blood vessel inflammation
Cold sores
US$ 1,555 dose
US$ 40,430 / year
IL-4Ra
US$ 3.5bn (AD approved in
2017, Asthma approved in
2018)
1 htps://icer.org/news-insights/press-releases/jak_inhibitor_evidence_report
Common side effects: nausea,
headache, and chest infections.
Black-box Warning: "increased risk of
serious infections, malignancy, and
thrombosis"
US$ 59,860 / year
(upadacitinib's annual list price for RA¹)
JAK1
US$ 0.7bn (RA only, approved in 2019)
|20View entire presentation